Neulasta (Amgen Inc)


Welcome to the PulseAid listing for the Neulasta drug offered from Amgen Inc. This Granulocyte Colony-Stimulating Factor [Chemical/Ingredient],Granulocyte-Macrophage Colony-Stimulating Factor [Chemical/Ingredient],Increased Myeloid Cell Production [PE],Leukocyte Growth Factor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Amgen Inc
NON-PROPRIETARY NAME: pegfilgrastim
SUBSTANCE NAME: PEGFILGRASTIM
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Granulocyte Colony-Stimulating Factor [Chemical/Ingredient],Granulocyte-Macrophage Colony-Stimulating Factor [Chemical/Ingredient],Increased Myeloid Cell Production [PE],Leukocyte Growth Factor [EPC]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2002-04-01
END MARKETING DATE: 0000-00-00


Neulasta HUMAN PRESCRIPTION DRUG Details:

Item DescriptionNeulasta from Amgen Inc
LABELER NAME: Amgen Inc
DEA SCHEDULE:
ACTIVE STRENGTH: 6(mg/.6mL)
START MARKETING DATE: 2002-04-01
END MARKETING DATE: 0000-00-00
PRODUCT ID: 55513-190_8a3c5a80-016e-4387-911b-dff02f966f33
PRODUCT NDC: 55513-190
APPLICATION NUMBER: BLA125031

Other PEGFILGRASTIM Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Amgen IncNeulasta